

Advancing Photonics for Health Care in Europe


Public Private Partnerships

Jürgen Popp



Translation Problem: the Valley of Death

D. Butler, Nature 453, 840-842 (2008)




TRL1	TRL2	TRL3	TRL4	TRL5	TRL6	TRL7	TRL8	TRL9
------	------	------	------	------	------	------	------	------

Basic Research

**Photonics21 PPP, EU
Funding
National Funding
Programs.**

**Digital Innovation Hubs,
Competence Centers**

Clinic



Photonics21 – Selected Milestones

April 2006



First European Strategic Research Agenda published and handed over to Commissioner Viviane Reding



Establishment of a Photonics Unit within the European Commission

Draft of a Multiannual Strategic Roadmap for Horizon 2020



Foundation of a PPP between Photonics21 and Photonics Unit

Draft of new Multiannual Strategic Roadmap for Horizon Europe



Foundation
European Technology Platform
Photonics21

2005

2006

2007-2013

2013-2020

2020-2027




PHOTONICS PUBLIC PRIVATE PARTNERSHIP




jenaphotonics®

Photonics21: Bottom-up Organisation and Structure of the Photonics Public Private Partnership




PPPP

- Lean Photonics21 Association as the PPP-contact partner of the EC
- Open, transparent and inclusive processes and structures
- Full control of the Photonics21 BoS over the Association
- Changes in the Terms of Reference:
 - New BoS members elected by Work Group members
 - Association financed by the BoS
 - BoS membership became institutional



Photonics21: Strategic Research and Innovation Agenda Process towards Horizon Europe – Standard Process Applied



2nd Workshop: Thursday, July 5th, Berlin, Leibniz-Geschäftsstelle



Photonics21: Europe's Age of Light – Our Vision & Missions for the next Decade

Instant diagnosis of major diseases

Sub-missions/Targets

- 1. Mobile/wearable photonics** devices and advanced **biosensors** for **instant** point-of-care (-use) **detection/diagnostics** and **treatment**, that measure the wearer's medical condition and wellness, wearables for monitoring environmental parameters
- 2. Photonic tools for life science industry as well as endusers** (e.g. medical doctors, research)
 - Photonic tools for real time proteomics, genomics, metabolomics.
 - Accelerating and enabling photonic tools for pharmaceutical industry, understanding, regenerative medicine, personalized medicine, high throughput high content screening
 - Photonic tools for understanding the origin of diseases beyond risk factors, finding pathways for treatment, photonics for health (nutrition, life style, environmental influences, toxicity)
- 3. Affordable photonics-based real time diagnostics** to stratify and classify disease status, monitor and assess treatment response will open the door to the practical implementation of precision medicine. **Optogenetics for treatment** of brain, heart diseases etc.; **Photonics for Physiological treatment**. Photonics for **interventional guidance** (Augmented reality). Multiscale access to the body (depth of penetration/optical resolution)
- 4. “vertical issues”**: Augmented reality, standardization, big data (data processing, AI, data mining)



Instant diagnosis of major diseases



National Photonic Funding Programs

- Only Germany has a dedicated Photonics Funding Program („Photonik Forschung Deutschland“)
- Usually other European countries do not even have specific photonics budgets. If photonics topics are currently on the national political agenda, they are usually addressed as a topic or a thematic priority in a broader technology or application context ("scope").
- At Innovate UK, e.g., this is the corresponding higher-level department "electronics, sensors & photonics".
- Austria uses the production program or the ICT program for photonics subsidies - depending on the topic.
- Other countries are promoting photonics through cross-cutting programs (e. g. "Innovation", "Emerging Technologies" etc.).
- Funding on a smaller level like e.g. the Irish Photonic Integration Centre (IPIC) or “Challenge Photonics” in France

→ **National / Regional initiatives and Digital Innovation Hubs gain importance**




Translation in Biophotonics:

How Innovation Hubs and Competence Centers Can Help.

The Challenge(s)

- Address the unmet medical need
- Develop the technological solution



© InfectoGnostics / European Commission

- Finding technological solutions within a highly regulated environment, e. g. for infection diagnostics (infectious agent, antimicrobial resistance)

The Challenge(s) Infectious Diseases

Epidemics



Irresponsible Use of
Antibiotics



Unavoidable use of
broad-spectrum antibiotics



Inappropriate therapy doubles
mortality risk


Medical Need: Precise Diagnostics for Targeted Therapy

- Need for rapid identification of pathogens and drug resistances – **diagnosis before therapy**
- Goal: fast, non-invasive diagnostics that are cost efficient
- Biophotonics is a key enabling technology for diagnostical purposes




© Shutterstock

Technology Proven, but What's Next? Scientist Left Alone



Translation Problem: the Valley of Death

D. Butler, Nature 453, 840-842 (2008)



Translation Problem: the Valley of Death

D. Butler, Nature 453, 840-842 (2008)



Basic Research

Clinic


- **Closing the gap** between basic research and application / clinics
- Organized as **public-private partnership (PPP)**
- Defined **handover points** to the industrial partners

FORSCHUNGS
CAMPUS

öffentlich-private Partnerschaft
für Innovationen

 **THE NEW
HIGH-TECH
STRATEGY**
Innovations for Germany

Value chain with gaps




Closed Value Chain – The Jena Solution

Knowledge-oriented basic research

Application-oriented basic research

Alliances/ joint application-oriented research

Product-oriented research

Development

Validation / clinical tests

Pro-duction Service



Research

Industrial Realization

Phase 1: Innovation Hub Organized as Public-Private Partnership

One stop shop along the value creation chain



- Services for research transfer and project control, networking from idea to market entry
- Mentoring by experienced entrepreneurs, support for the start-up companies - 4 founded so far
- Infrastructure: laboratories, esp. photonic instrumentation, biosafety labs, access to clinical samples and clinical experts
- Impact on teaching/ education:
 - Master in medical photonics (Univ. of Jena) started 2016
 - Diagnostics-oriented graduate program



InfectoGnostics Labs @Jena University. Germany

Example: Portable Device for Raman Spectroscopical Detection of Pathogens and Resistance Profiles

Raman spectroscopy-based diagnostics





Identification of single microbes without cultivation (realtime)

Example: Portable Device for Raman Spectroscopical Detection of Pathogens and Resistance Profiles

Future of Raman spectroscopy

2015  2020



200,000  3,000 EUR




Cost-efficient
miniaturized Raman
Spectrometer:
Raman2GO


The Solution - Microfluidics and Spectroscopy and Imaging

Development of a analytical system for urin diagnostics

Concept: plate with microwells



Principle of function of a chip with 20 wells a); side view of a well inside of the chip b); top view of a well with integrated electrodes c).



Glas chip with electrode structures for 4x5 test areas


Circuit board PDMS-cover with 4 x 5 wells

Pictures of the test platform (76 x 26 mm²) with integrated circuit board, glass plate with electrodes and PDMS well cover for four different antibiotics.


Development of a analytical system for urin diagnostics

Results of the first experimental test runs:

The developed platform is able to capture bacteria for further imaged-based analysis and raman spectroscopy.



Picture of a captured bacteria cloud with DEP



Videos of the capture porcess of bacteria (left) and the division of bacteria in culture medium (right). Concentration 3×10^3

Detection of AMR and MIC

E. coli strain	Ciprofloxacin concentration [mg/L]												Raman Classification	MIC [mg/L]	BMD MIC [mg/L]
	0	0,008	0,016	0,032	0,064	0,125	0,25	0,5	1	2	4	8			
AG100	✓	✓	✓	✓	✗	✗							S	0,032	0,032
	✓		✓	✓	✗	✗	✗	✗	✗				S	0,032	
	✓		✓	✓	✗	✗	✗	✗	✗				S	0,032	
3-AG100	✓							✓	✓	✗	✗	✗	R	1	1
	✓							✓	✓	✗	✗	✗	R	1	
	✓							✓	✓	✗	✗	✗	R	1	
387	✓				✓	✗	✗	✗	✗				S	0,064	0,032
	✓		✓	✓	✓	✗	✗	✗	✗				S	0,064	
405	✓					✓	✓	✓	✓	✗			R	1	0,5 - 1
407	✓					✗	✗	✗	✗	✗			S	≤ 0,125	0,016
416	✓						✓	✓	✓	✓	✓		R	> 4	1
	✓							✓	✓	✓	✓	!	R	4	
422	✓						✓	✓	✓	✓	✗		R	2	1
500	✓					✓	✓	✓	✓	✗			R	1	0,5
	✓						✓	✓	✓	✗	✗		R	1	
539	✓				✓	✓	!	!	✗				S	0,125	0,25
	✓						✓	✓	!	✗	✗		S	0,25	
544	✓						✓	✓	✓	✓	✓		R	> 4	≥ 32
545	✓	✓	✓	✓	✓	✗							S	0,064	0,125
	✓			✓	✓	!	✗	✗					S	0,064	
554	✓						✓	✓	✓	✓	✓		R	> 4	≥ 32
579	✓						✓	✓	✓	✓	✓		R	> 4	≥ 32
673	✓	✓	✓	!	✗	✗							S	0,016	0,032
683	✓	✓	✓	!	✗	!							S	0,016	0,032
	✓		✓	!	!	!	✗	✗	✗				S	0,016	

Phase 2: Innovation Hub Plus Competence Centre

- **Competence Centre for photonics in infection research**
located directly at Jena University Hospital
- State-of-the-art plus emerging technologies
(e.g. XUV microscope, super-resolution Raman)
- From nanoscale to macro (molecule to first-in-man)
- Technological workflow from sample preparation to the solution
(incl. SOP development)
- Clinical expertise directly influences technology development
- Pipeline concept for a **closed value chain**



The LPI @Jena concept: www.lpi-jena.de





LEIBNIZ CENTER *for*
PHOTONICS *in*
INFECTION RESEARCH




Going Beyond the Limits

LPI's Diagnostic Service Pipeline



More than Diagnostics: Therapeutic Approaches



LPI's Therapeutic Service Pipeline



Examples of Therapeutic Approaches

- treatments with new anti-infective drugs or recombination of existing active substances,
- topical treatment of wounds, eg by using:
 - nonwovens that are releasing reactive oxygen species, photosensitizers, phage therapy, plasma medicine
- treatment with stimulated pathogen-specific T cells
- treatments with antibiotic theragnostic nanoparticles to make the substances bioavailable where needed in the body

> “first in man / first in patient”-unit




Top: SmartDyeLivery GmbH

Bottom: kinPEN, neoplas tools GmbH.

Future of Networking: Regional Innovation and Competence Centres

DIGITAL INNOVATION HUB

- Making use of CCs for equipment and expertise
- Development of ecosystem
- Support of brokerage
- Access to finance
- Market intelligence
- Training and education
- Incubator services
- *Supporting the innovation ecosystem*



COMPETENCE CENTRE

- Technological infrastructure, technology platform
- Available expertise to make it operational
- Support of experimentation in business environment
- Showing best practices
- *Sharing costs and development of expertise*

Thank You.